Most Popular Stories
- Walgreens plans 100 more retail clinics by mid-2009
- Disruptive doctor behavior causes mistakes, intimidates workers
- AHA survey: Negative profit margins for hospitals
- DOD, VA move to SOA architecture to build interoperable systems
- HHS: 60 percent of DME companies banned by Medicare may keep billing
- Cleveland Clinic lists potential conflicts of interest online
Poll
Featured Jobs
-
Texas Dir. of Med/Surg
StaffPointe, LLC - east , TX -
Georgia Invasive Cardiologist
StaffPointe, LLC - southeast coast , GA -
Tennessee Family Practice
StaffPointe, LLC - east , TN -
Florida RN Emergency Room
StaffPointe, LLC - St. Petersburg , FL -
Texas Urgent Care Physician CEx1154
StaffPointe, LLC - near Sherman , TX
Events
- Avaya Patient Payment Recovery Webinar
Thursday, December 11, 2008 1-2pm
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
- Emerging markets series: Benchmarking key countries Brazil, Russia, India, China and Turkey
Popular Topics
FL sues Merck over Vioxx marketing
Florida's Attorney General has filed suit against Merck & Co., again, this time for allegedly deceptive marketing and promotion of joint pain drug Vioxx. The suit claims that Merck failed repeatedly to disclose the drug's adverse effects, while offering it to the state's Medicaid program as a safe painkiller, in direct violation of the state's Deceptive and Unfair Practices Act.
Vioxx has been off the market since 2004, when studies suggested that users had a greater risk of heart attack and stroke if they engaged in long-term use of the drug. Attorney General Bill McCollum has been investigating for three of the four years since the market pullout. His research concluded that the Florida Medicaid program spent $80 million on the drug between 1999 and 2004.
In the suit, McCollum contends that Merck tried to bully physicians and researchers who questioned the drug's safety, while possibly misrepresenting or concealing published evidence showing harmful side effects.
The lawsuit demands restitution to the state, plus interest, for all state program payments for Vioxx. It also seeks civil money penalties of up to $10,000 per violation.
To learn more about the suit:
- read this South Florida Business Journal piece
Related Articles:
Despite safety issues, Vioxx still in demand
Merck settling Vioxx claims for $4.85B
Related Stories
- Jury awards Ernst $253.5M in Vioxx suit
- Fourth Vioxx trial begins
- Merck documents may worsen company's case
- Vioxx verdict shocks markets
- Gilmartin testifies in Vioxx suit
- SPOTLIGHT: Hung jury forces mistrial in Vioxx suit
- Merck agrees to $58M settlement on Vioxx ads
- Justice Department recovers $1.12 billion from fraud
- Merck doctor testifies in Vioxx trial
- Pivotal week in Vioxx trial
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





